New research reveals that individuals who come off new GLP-1 drugs like semaglutide or tirzepatide may regain shed pounds much more quickly than those who end conventional diet and exercise programs.
Published data in a leading health publication points out that while obese individuals often shed substantial amounts of their total mass while on the medication, the mass is regained at an average rate of 0.8 kg per month once they quit.
"Individuals buying such treatments should be aware of the risk of quick weight regain when the therapy ends," cautioned lead investigator Dr. Susan Jebb.
Such speed of regain implies a reversion to starting mass in about one and a half years.
Analyzing Approaches
The study, which examined dozens of trials involving over 9,000 of patients, compared the outcomes of these new drugs with older methods.
Researchers emphasize that people who lose weight through lifestyle changes alone typically see a slower weight regain—around 100 grams monthly—once they finish.
Explaining the Rapid Regain
Nutrition scientists propose the mode of action of the injections accounts for the accelerated rebound.
GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which controls appetite.
"Artificially providing GLP-1 concentrations far above than normal might result in the body to generate a reduced amount of its own natural GLP-1, and could reduce responsiveness to its effects," said Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this GLP-1 'fix' leads to hunger is no longer kept in check, making excessive eating a significant risk."
A Chronic Issue?
Health authorities recommend the jabs for people with obesity-related health risks, alongside prescribed lifestyle changes.
Many experts say that, given the high risk of relapse, the treatment is often ongoing.
This perspective is reinforced by drug manufacturers, who state that the results "emphasize the chronic character of excess weight," comparing it to managing diseases like hypertension.
Patient Experiences
Individuals who have stopped the jabs report a intense return of appetite.
"It was like something that goes on and you become extremely hungry," recalled an individual.
This difficulty is exacerbated if users have not established lasting lifestyle or habit modifications during therapy.
Growing Interest
Figures indicate that a significant number of adults in the UK have tried these injections in the past year, with desire being substantial.
- Adoption is higher among females than males.
- The middle-aged age group shows the highest level of interest.
- A large proportion obtain the drugs through private healthcare rather than the NHS.
In conclusion, researchers caution that while these medications are potent tools for shedding pounds, they are not a standalone fix and lasting health benefits hinges on integrated lifestyle support.
